Lisata Therapeutics Tender Offer Extended Again — 64.67% of Shares Tendered, Deadline Pushed to July 20

summarizeSummary

Lisata Therapeutics' acquisition by Kuva Labs hits another delay: the tender offer deadline is now July 20, with 64.67% of shares tendered so far, and the merger outside date pushed to July 21.

check_boxKey Events · M&A and Partnerships · LSTA

• Tender Offer Extended to July 20

  The purchaser has pushed the expiration time from July 16 to 11:59 p.m. on July 20, 2026, marking the third extension since the offer commenced on June 10.

• 64.67% of Shares Tendered

  As of July 15, approximately 5,897,848 shares have been validly tendered, representing 64.67% of the 9,119,742 outstanding shares — still below the typical 90% short-form merger threshold.

• Merger Outside Date Extended to July 21

  An amendment to the Merger Agreement extends the outside date from July 17 to July 21, 2026, giving the parties four additional days to close.

• Going Concern Risk Persists

  Lisata previously disclosed substantial doubt about its ability to continue as a going concern; if the tender offer fails, the company would be left with limited cash and no immediate alternative.

auto_awesomeAnalysis · LSTA · Life Sciences

For the third time, the tender offer for Lisata Therapeutics has been extended, now to July 20, 2026, while the merger outside date moves to July 21. As of July 15, 64.67% of outstanding shares have been tendered, still short of the typical 90% threshold for a short-form merger. The repeated extensions, set against a going concern warning and prior delays, signal continued uncertainty around deal closure. Should the offer fail, Lisata faces severe liquidity pressure with no clear alternative.